Unicycive Stock Analysis

UNCY -  USA Stock  

USD 2.81  0.05  1.81%

The big decline in price over the last few months for Unicycive Therapeutics created some momentum for investors as it was traded today as low as 2.75 and as high as 2.89 per share. The company executives failed to add value to investors and positioning the company supply of money to exploit market volatility in July. However, diversifying your holdings with Unicycive Therapeutics or any similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 11.29. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Unicycive Therapeutics partners.
Also, please take a look at World Market Map.

Search Stock Analysis 

The Unicycive Therapeutics stock analysis report makes it easy to digest most publicly released information about Unicycive Therapeutics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Unicycive Stock analysis module also helps to analyze the Unicycive Therapeutics price relationship with some important fundamental indicators such as market cap and management efficiency.

Unicycive Stock Analysis Notes

The company had not issued any dividends in recent years. Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. The company was incorporated in 2016 and is based in Los Altos, California. Unicycive Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 1 people. For more information please call the company at 650 351 4495 or visit http://www.unicycive.com.

Unicycive Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Unicycive Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Unicycive Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Unicycive Therapeutics generates negative expected return over the last 90 days
Unicycive Therapeutics has high historical volatility and very poor performance
The company currently holds 3.48 M in liabilities. Unicycive Therapeutics has a current ratio of 0.13, indicating that it has a negative working capital and may not be able to pay financial obligations when due.
Net Loss for the year was (2.88 M).
Unicycive Therapeutics currently holds about 147 K in cash with (2.06 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02.
Latest headline from www.equities.com: Unicycive Therapeutics Inc falls 3.16 percent for July 30 - Equities.com

Unicycive Market Capitalization

The company currently falls under 'Micro-Cap' category with current market capitalization of 53.13 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Unicycive Therapeutics's market, we take the total number of its shares issued and multiply it by Unicycive Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Management Efficiency

Unicycive Therapeutics management efficiency ratios could be used to measure how well unicycive therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 3rd of August, Unicycive Therapeutics has the coefficient of variation of (631.51), and Risk Adjusted Performance of (0.26). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Unicycive Therapeutics, as well as the relationship between them. In other words, you can use this information to find out if the company will indeed mirror its model of past prices and volume data, or the prices will eventually revert. We were able to break down nineteen technical drivers for Unicycive Therapeutics, which can be compared to its competition. Please validate Unicycive Therapeutics coefficient of variation, maximum drawdown, as well as the relationship between the Maximum Drawdown and skewness to decide if Unicycive Therapeutics is priced more or less accurately, providing market reflects its prevalent price of 2.81 per share. Please also confirm Unicycive Therapeutics total risk alpha, which is currently at (1.47) to double-check the company can sustain itself at a future point.

Unicycive Therapeutics Price Movement Analysis

Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Moving Average is predictive technique used to analyze Unicycive Therapeutics price data points by creating a series of averages of different subsets of Unicycive Therapeutics entire price series. View also all equity analysis or get more info about all moving average overlap studies indicator.

Unicycive Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Unicycive Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Unicycive Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Unicycive Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Unicycive Therapeutics Predictive Daily Indicators

Unicycive Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Unicycive Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Unicycive Therapeutics Forecast Models

Unicycive Therapeutics time-series forecasting models is one of many Unicycive Therapeutics' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Unicycive Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Unicycive Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Unicycive Therapeutics stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Unicycive shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Unicycive Therapeutics. By using and applying Unicycive Stock analysis, traders can create a robust methodology for identifying Unicycive entry and exit points for their positions.
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. The company was incorporated in 2016 and is based in Los Altos, California. Unicycive Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 1 people.

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Unicycive Therapeutics to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Price Exposure Probability Now


Price Exposure Probability

Analyze equity upside and downside potential for a given time horizon across multiple markets
All  Next Launch Module
Also, please take a look at World Market Map. Note that the Unicycive Therapeutics information on this page should be used as a complementary analysis to other Unicycive Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.

Complementary Tools for Unicycive Stock analysis

When running Unicycive Therapeutics price analysis, check to measure Unicycive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unicycive Therapeutics is operating at the current time. Most of Unicycive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Unicycive Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Unicycive Therapeutics' price. Additionally, you may evaluate how the addition of Unicycive Therapeutics to your portfolios can decrease your overall portfolio volatility.
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
The market value of Unicycive Therapeutics is measured differently than its book value, which is the value of Unicycive that is recorded on the company's balance sheet. Investors also form their own opinion of Unicycive Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Unicycive Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Unicycive Therapeutics' market value can be influenced by many factors that don't directly affect Unicycive Therapeutics underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Unicycive Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Unicycive Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Unicycive Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.